40results about "Filtration" patented technology

The invention discloses a clean storage system for a household breathing machine. The machine body is provided with a breathing machine placing area, a storage device, an air purification system and a display control component, an air outlet is at least formed in the breathing machine placing area or the part, close to the breathing machine placing area, of the machine body, the storage device is provided with a storage chamber, an exhaust port and a storage port capable of being opened and closed, and the storage chamber is communicated with an air supply device. The air purification system is provided with a fan, an air purification device, an air outlet and an air inlet, an airflow channel in the machine body in the air outlet direction of the air purification device is a clean air area, the air outlet communicates with the airflow channel, the breathing machine containing area forms the clean air area, and the air supply device sucks clean air. The household breathing machine platform has a special platform space for placing various types of household breathing machines, has an air source filtering and purifying function, and has the advantages that accessories / parts of the household breathing machines can be cleanly stored, indoor environment air can be purified, and the like.

Disclosed is a method for filtering a fibrinogen composition, including the following steps: a) purifying the fibrinogen composition by chromatographic purification using an elution buffer comprising arginine; b) optionally, at least one step of filtering the fibrinogen composition obtained by chromatographic elution in step a), on a filter having a pore size of between 0.08 μm and 0.22 μm, c) filtering the fibrinogen composition obtained by chromatographic elution in step a), or optionally obtained in step b), on a symmetrical filter having a pore size of between 15 nm and 25 nm, and preferably between 18 nm and 22 nm, and d) recovering the resulting fibrinogen solution, the filtering method being carried out without adding arginine after step a), at a high capacity and without a prior freezing and / or thawing step.

Compositions are provided for the formulation of theta defensins and / or theta defensin analogs that are highly suitable for parenteral administration. Compositions are provided for the formulation of theta defensins and / or theta defensin analogs that are highly suitable for parenteral administration.SOLUTION: Such formulations provide the theta defensin and / or theta defensin analog in a slightly acidic buffer containing propylene glycol. Surprisingly, the inventors have found that such formulations increase the bioavailability of θ-defensins and / or θ-defensin analogues so provided by at least a factor of 10 compared to conventional isotonic saline solutions, and dramatically improve bioavailability in human subjects compared to animal models. The inventors have also found that such formulations advantageously exhibit low viscosity at high peptide concentrations, allowing reduced injection volumes and sterilization by simple filtration.SELECTED DRAWING: Figure 2

A purification device (2) for sterilizing and filtering intake air (4) is disclosed. The purification device (2) includes a housing (10) having a number of inlet holes (8) for allowing the intake air (4) to enter and a number of outlet holes (8') for allowing the air (6) purified by the purification device (2) to leave. The purification device (2) further includes a fan (12) disposed inside the housing (10) for drawing the intake air (4) into the housing (10) and blowing the purified air (6) out of the housing (10). The purification device (2) further includes an ultraviolet radiation lamp (14) disposed inside the housing (10) for irradiating the intake air (4). The purification device (2) further includes a high-efficiency particulate air (HEPA) filter (20) disposed to filter the intake air (4) before it leaves the housing (10) as purified air (6). The filter (20) has a plurality of pleats (32) arranged such that the angle (θ) between adjacent pleats (32) is 30° or less.

The present invention provides a pharmaceutical preparation in which an aqueous pharmaceutical composition, which contains (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof, is housed in a packaging that blocks light rays of 210-380 nm in wavelength. In this pharmaceutical preparation, the stability of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in the aqueous pharmaceutical composition has been improved.

Disclosed is a clean storage system for a home ventilator, including a body with a ventilator placement region, storage device, air purification system, and display control component. Air outlets are at least formed in the ventilator placement region or a portion of the body proximal to the ventilator placement region. The storage device is provided with a storage chamber, exhaust ports, and a storage opening being opened or closed. The storage chamber communicates with an air supply device. The air purification system is provided with a fan, an air purification device, the air outlets, and air inlets. An airflow channel in an air outflow direction of the air purification device in the body is a clean air region, and the air outlets communicate with the airflow channel, such that a clean air area is formed in the ventilator placement region, and the air supply device draws in clean air.

The present invention relates to a method for sterile filtration of an albumin-containing aqueous solution (2), wherein the method comprises filtering the solution (2) with at least one filter (3) to obtain a filtrate (1), wherein the at least one filter (3) is conditioned prior to filling the filtrate (1) into at least one container (10, 10') by purging the at least one filter (3) with a quantity (5) of the albumin-containing aqueous solution (2) i) at a differential pressure across the respective filter (3) of at most 1 bar and / or ii) by means of pressure filtration, wherein the filtrate (1) is maintained in the outlet (4) of the respective filter (3) at a back pressure of at least 0.5 bar is maintained.

The present invention relates to a method for the sterile filtration of an aqueous albumin-containing solution (2), where the method comprises filtering the solution (2) with at least one filter (3) to obtain a filtrate (1), where the filtrate (1) is filled in at least one container (10, 10 ') before the filtrate (1) is filled in the at least one container (10, 10'), the at least one container (10, 10 ') is filled in the at least one container (10, 10'). The at least one filter (3) is conditioned by washing the at least one filter (3) with an amount (5) of the albumin-containing aqueous solution (2) under the following conditions: i) at a differential pressure across the respective filter (3) of at most 1 bar and / or ii) by means of pressure filtration, wherein the filtrate (1) is maintained at a back pressure of at least 0.5 bar in the outlet (4) of the respective filter (3).

An apparatus (1) for applying a coating to an injection medical device, comprising a feed tank (10) loadable with a coating substance, an output nozzle (80) for delivering the coating substance to the injection medical device, and a supply assembly (20) interposed between and in fluid communication with the feed tank (10) and the output nozzle (80) for removing the coating substance from the feed tank (10) and supplying it to the output nozzle (80). The supply assembly (20) comprises at least one sterilizing filter (30a, 30b) for filtering the coating substance removed from the feed tank (10).

A method for preparing a filtered beverage includes filtering a raw beverage using a cross-flow ultrafiltration device to produce a solids fraction and a liquid fraction; heating the solids fraction to a temperature of 60° C. or greater to produce a pasteurized solids fraction; microfiltering the liquid fraction through a microfilter having a size cut-off of 1 μm or smaller to produce a microfiltered liquid fraction; and combining the pasteurized solids fraction and the microfiltered liquid fraction to result in the filtered beverage.

This paper describes a method for producing a sterile in-situ gel based on solvent removal technology, and the resulting product. Compared to conventional aseptic manufacturing methods for in-situ gel formulations, this method adds a volatile solvent during production to reduce the viscosity of the formulation solution, facilitating filtration and sterilization. The volatile solvent can then be removed by various methods without adversely affecting the final in-situ gel formulation. Research data shows that the volatile solvent residues in in-situ gel formulations produced using this method meet safety standards. Compared to formulations produced using the conventional radiation sterilization method, the types and amounts of degradation impurities in the polymer and active pharmaceutical ingredients are both reduced, further improving the safety of the formulation.

The invention relates to a method for inactivating an enveloped virus in a biopharmaceutical-containing fluid, said method comprising exposing said fluid to a substituted cyclodextrin. The invention also relates to a method for purifying and / or producing a biopharmaceutical comprising exposing a biopharmaceutical-containing fluid to a substituted cyclodextrin.

Metal working fluid decontamination apparatus (10) includes: an intake arrangement (40) for metal working fluid (42); a pump (16) for providing, in use, flow pressure to the metal working fluid (42); a decontaminator (50) for reducing contamination in the metal working fluid (42); and an outlet arrangement (34) for the metal working fluid. The metal working fluid (42) is a fully synthetic metal working fluid, which comprises water and a water soluble synthetic concentrate which does not comprise oil.

The present invention provides a pharmaceutical preparation comprising an aqueous pharmaceutical composition comprising (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof, wherein the aqueous pharmaceutical composition is stored in a package which blocks a light having a wavelength of from 210 to 380 nm, in which the stability of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or the salt thereof in the aqueous pharmaceutical composition is improved.

A filter cartridge for a sterilizing cabinet includes a first gasket comprising a rigid or flexible edge portion and forming a frame defining a hollow center portion, a first filter comprising a porous material for maintaining a sterilized condition in the sterilizing cabinet and passing gaseous materials through the porous material, wherein the first filter is affixed to the first gasket, and a second filter comprising a porous material for maintaining a sterilized condition in the sterilizing cabinet and passing gaseous materials through the porous material, wherein the second filter is either affixed to the first filter or the first gasket opposite the first filter, and wherein the filter cartridge provides sufficient structural integrity to form a sealing interface with a confronting surface of the sterilizing cabinet.

The embodiments disclose a system is disclosed for producing humic and fulvic acid compositions suitable for human consumption. The system includes a water treatment module configured to process various water sources—such as chlorinated municipal water, unchlorinated well water, spring water, or ocean water—through particulate filtration, desalination, dichlorination, defluorination, sterilization, and pH adjustment to maintain a level between 8.5 and 10. A humate source preparation module chops and pulverizes humate sources including humus soil, coal, degradated plant matter, or mineral-rich waters. A mixing tank combines the treated water with the pulverized humate. A separation module comprises at least one chamber containing activated carbon and a pH / temperature control device to isolate and direct fulvic acid to a fulvic acid storage tank and humic acid to a humic acid storage tank. Both acids are suspended in treated water and stored for subsequent use in consumable products, including beverages and supplements.

Disclosed is a method for disinfecting and cleaning to prevent contamination of a passenger vehicle, characterized in that it includes the following operations:—installing at least one filter and condenser in the ventilation circuit; creating a swirling vortex of a disinfectant liquid by a gas referred to as a driving gas; spraying the swirling mixture created onto the clothing and luggage of passengers before they enter the passenger compartment; and spraying the mixture created onto the solid surfaces and / or into the air of the passenger compartment to be disinfected. Also disclosed is a device for implementing the method.

A contrast therapy machine is disclosed. The contrast therapy machine includes a cavity that is sized and shaped to accommodate one or more human bodies. Single user contrast therapy machines may include an opening through a top surface permitting the human body from the neck up to be outside of the contrast therapy machine while it is use. The contrast therapy machine includes a heater and a cooler. The contrast therapy machine can switch automatically or be manually switched between one or more cooling cycles and one or more heating cycles. Heating cycles and cooling cycles may be customized.

This decontamination apparatus is configured to decontaminate at least one of microorganisms and viruses present inside an object to be decontaminated. A filter for removing particles is attached to the inside of the object to be decontaminated. The decontamination apparatus comprises a steam generation part and a pump. The steam generation part is configured to generate steam containing peracetic acid without heating and without releasing mist. The pump is configured to suck the steam from the exhaust side of the filter for removing particles and to supply the steam to the air supply side of the filter for removing particles. This decontamination apparatus is used in a state of being disposed outside the object to be decontaminated.

Devices, systems, and methods for reprocessing endoscopic devices include a cabinet for drying and holding disinfected endoscopes after use. A protective layer surrounds a frame that holds the endoscopes. The frame can be assembled by hand. The protective layer includes a filtered air inlet and filtered air outlet. UV lights aid the disinfection and drying of the endoscopes.

Devices, systems, and methods for reprocessing endoscopic devices include a cabinet for drying and holding disinfected endoscopes after use. A protective layer surrounds a frame that holds the endoscopes. The frame can be assembled by hand. The protective layer includes a filtered air inlet and filtered air outlet. UV lights aid the disinfection and drying of the endoscopes.

A light fixture includes a housing forming a cavity to permit airflow therethrough. A filter is disposed within the airflow of the cavity. An ultraviolet light emitting diode is disposed within the cavity and is directed to concurrently treat the airflow and the filter to destroy biomaterial therein.

Storage stable aqueous ready-to-administer formulations comprising isoproterenol are presented with desirable stability characteristics. In preferred aspects, formulations are terminally sterilized and packaged in a suitable format, such as a polymeric bag with metalized overwrap and include a non-contact oxygen scavenger.

A clean storage system for a home ventilator includes a body with a ventilator placement region, a storage device, an air purification system, and a display control component, where air outlets are at least formed in the ventilator placement region or a portion of the body proximal to the ventilator placement region; the storage device is provided with a storage chamber, exhaust ports, and a storage opening capable of being opened or closed, and the storage chamber communicates with an air supply device; the air purification system is provided with a fan, an air purification device, the air outlets, and air inlets; and an airflow channel in an air outflow direction of the air purification device in the body is a clean air region, and the air outlets communicate with the airflow channel.

A method of preparing a bioprocess solution includes producing a mixture of liquid and air by hydrating a powder separating the liquid from the air by providing the mixture to a first filter capsule and allowing the liquid to flow to an outlet across a hydrophilic membrane of the first filter capsule while directing the air upwards along the first filter capsule toward a second filter capsule arranged above the first filter capsule, and venting the air from the second filter capsule by allowing the air to flow through a hydrophobic membrane of the second filter capsule.

The invention belongs to the technical field of superoxide dismutase preparation, and particularly relates to a preparation method of SOD condensate stock solution for inflammation relief, which comprises the following steps: SOD enzyme source raw material selection and pretreatment: recombinant human Cu / Zn-SOD is selected as a preferred enzyme source, and the specific activity of the recombinant human Cu / Zn-SOD is greater than or equal to 6000 U / mg protein; or selecting a plant source such as spinach and garlic, or a microbial source such as SOD fermented by bacillus subtilis as an alternative enzyme source; gel filtration chromatography (GFC) is adopted for purifying the selected SOD, impure protein and endotoxin are removed, and the purity is larger than or equal to 95%; the preparation method of the SOD condensate stock solution for relieving inflammation has high activity and stability: dissolved oxygen (less than or equal to 2mg / L) in water is reduced through vacuum low-temperature condensation (0-5 DEG C), and SOD oxidation inactivation is reduced; recombinant human source SOD or plant / microorganism source SOD is selected according to different requirements, and the requirements of multiple scenes such as adjuvant therapy of inflammatory skin diseases, anti-inflammatory skin care products and the like can be met through fine adjustment of technological parameters.

The invention relates to a closure device for closing a pharmaceutical container, having a closure tool for engaging a closure element to a pharmaceutical container (68), having a fluid unit for applying at least one gaseous fluid to the container, having at least one filter (64, 66), wherein the closure device (10) has a tool receptacle (14) and a tool unit (18), wherein the tool unit (18) is designed as a module which can be repeatedly detached from or connected to the tool receptacle (14) by means of a coupling device (16) and which comprises the closure tool (42), the fluid unit (90) and at least one filter (66, 68).

The present disclosure provides compositions and methods for inactivating lipid-enveloped viruses in product feedstreams in therapeutic protein manufacturing processes using environmentally compatible surfactants. The present invention provides a surfactant mixture that includes two environmentally sustainable surfactants, n-octyl-β-D-glucopyranoside (OG) and n-dodecyl-β-D-maltopyranoside (DDM). The performance of this OG:DDM surfactant combination has been compared to lauryl dimethylamine oxide (LDAO), ECOSURF, and EDTA in the purification of therapeutic proteins such as abatacept and belatacept. (商標) EH9, or Triton X-100. The OG:DDM combination is highly effective at viral inactivation, but has essentially no effect on protein stability, protein charge distribution (e.g., sialic acid levels), impurity clearance, protein deamination, or protein oxidation. Thus, the OG and DDM combination can be used as an alternative to Triton X-100 for the viral inactivation step in the manufacturing of biologics.

The present invention relates to a method for producing a sterile product containing heat labile and / or bioactive ingredients. The method includes a step of filter-sterilizing the product.Preferably, the sterile product obtained by the method of the invention is intended for cosmetic use, more preferably for use in cosmetic mesotherapy, such as anti-aging mesotherapy, or for medical use in aesthetic medicine or dermatology, preferably as an injectable.The method of the invention is particularly preferred for the production of sterile hyaluronic acid or its derivatives.